GRANULES
GenericsGRANULES is a generic drug manufacturer focused on Neurology, Cardiovascular, Gastroenterology.
GRANULES's Key Drugs
GRANULES's core commercial portfolio centers on ACETAMINOPHEN AND IBUPROFEN, NAPROXEN SODIUM AND DIPHENHYDRAMINE HYDROCHLORIDE, GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, spanning Neurology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
GRANULES's Recent FDA Approvals
New NDA/BLA approvals for GRANULES over the last two years — novel drugs only, excluding generics and label supplements.
GRANULES's Therapeutic Areas
GRANULES's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GRANULES's Top Competitors
GRANULES's closest competitors by therapeutic-area and drug-target overlap include Merck, Novo Nordisk, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GRANULES Pipeline Snapshot
Active clinical trials for GRANULES across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ACETAMINOPHEN AND IBUPROFEN leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (3)
Discontinued (0)
Company Info
- First Approval
- 1993-12-21
- Latest
- 2026-06-18
- Applications
- 65